Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Benitec Biopharma has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $98.2 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $98.2 million, up 449.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $129.2 million (up 62.3% YoY), and the FY2025 annual result was $70.5 million, up 3.61% from the prior year.
• Cash from Financing Activities came in at $98.2 million for Q4 2025 at Benitec Biopharma, up from $2.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.2 million in Q4 2025 to a low of $3000.0 in Q1 2021.
• The 5-year median for Cash from Financing Activities is $17.9 million (2024), against an average of $24.1 million.
• Across the five-year window, Cash from Financing Activities jumped 45720.51% in 2024 and plunged 93.65% in 2025, its largest moves.
• Benitec Biopharma's Cash from Financing Activities stood at $12.7 million in 2021, then increased by 26.42% to $16.0 million in 2022, then slumped by 99.76% to $39000.0 in 2023, then surged by 45720.51% to $17.9 million in 2024, then surged by 449.69% to $98.2 million in 2025.
• The last three Cash from Financing Activities figures came in at $98.2 million (Q4 2025), $2.5 million (Q2 2025), and $28.4 million (Q1 2025), per Business Quant data.